MedTrace Logo

To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames

NCT03975205 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2019-06-05

No results posted yet for this study

Summary

Doxil or Doxorubicin to be administered was administered in a dose of 50 mg/m2 as infusion over 15 minutes. Blood samples to be obtained at 0, 1, 2, 3, 4, 8, 12, 24, 48 and 72 hours

Conditions

  • Lymphoma Leukemia

Interventions

DRUG

Doxorubicin

To measure bioavailabity of Doxil versus Doxorubicin

Sponsors & Collaborators

  • Bharath Charitable Cancer Hospital and Institute

    collaborator OTHER

  • Sutphin Drugs

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2019-10-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03975205 on ClinicalTrials.gov